Explore this article's sources with AI
Follow PeptideMethods on Google
Reading a reply about the HISTORI trial
A new letter responds to a comment on the HISTORI semaglutide analysis. Its indexed record confirms correspondence, not the content of either letter.
Why we wrote this. A new response letter could invite overreading. The public record supports a narrower account of what the correspondence and the underlying trial report establish.
In this article (6 sections)
A new Diabetes Care record is a response to a comment about the HISTORI semaglutide analysis. The response is a letter, and the reachable PubMed record supplies a title and DOI but no abstract or full text. That matters. The record confirms that an exchange took place. It does not reveal the comment's argument or the authors' reply.[1] This explainer therefore separates the documented paper from claims that the available response record cannot support.
What the new record actually establishes
PubMed lists the response as a Letter in Diabetes Care, published online on 20 October 2026. Its title identifies it as a response to a comment on Ganeshalingam and colleagues' report of the HISTORI trial analysis of insulin sensitivity and beta-cell function. The title describes a 30-week randomized, placebo-controlled semaglutide study.[1] Those are bibliographic facts, not a transcript of either letter.
The preceding comment is also indexed as a Letter in Diabetes Care. Its record has no abstract. Its title repeats the secondary-analysis title, rather than stating a criticism in the metadata that is reachable here.[2] It would be wrong to reconstruct the disagreement from the indexed titles or from the fact that a response exists.
The study behind the exchange
The underlying secondary analysis is available in full text. It reports a double-blind, parallel-group, multicenter randomized trial in Denmark. Investigators randomized 154 adults with schizophrenia-spectrum conditions, prediabetes, overweight or obesity, and second-generation antipsychotic treatment to semaglutide or placebo. The intervention period was 30 weeks, and 141 participants completed the trial.[3]
This was not a trial of semaglutide for schizophrenia symptoms. The published analysis examined metabolic measures. The authors report that insulin sensitivity improved more with semaglutide than with placebo, while the reported increase in beta-cell function was not statistically significant. They also report lower fasting glucose and a reduction in insulin resistance relative to placebo.[3] Those findings belong to the accessible study report, not to the later reply letter.
Why a response letter needs a narrow reading
A response can clarify a method, defend an interpretation, correct a detail, or address a concern raised by correspondents. Its mere publication does not tell readers which of those things happened. It also does not automatically alter the trial's estimates, create a new outcome, or settle a clinical question. Here, the abstract-free record does not allow us to attribute a specific position to the correspondents or the trial authors.[1]
That boundary is especially useful in clinical reading. A reader can say that a letter-and-response exchange exists around the HISTORI analysis. A reader cannot responsibly say that the response disproved a criticism, that the comment uncovered an error, or that either letter changed the treatment effect. Those claims require the text of the letters and, where relevant, a correction or updated analysis from the journal.
What the accessible trial report can support
The full report describes insulin sensitivity, insulin resistance, fasting glucose, fasting insulin, C-peptide, and HOMA2 estimates as study measures. It reports complete insulin data at both time points for 131 participants. Its analysis found a treatment effect of 8.60 for insulin sensitivity, with a 95% confidence interval from 5.82 to 13.65, and a treatment effect of minus 0.69 for insulin resistance, with a 95% confidence interval from minus 1.00 to minus 0.20.[3]
The report also gives reasons to keep the interpretation measured. It is a 30-week trial in a defined population and setting. The investigators describe the paper as a prespecified secondary-end-point analysis, while the trial's prespecified primary end point was change in HbA1c.[3] A secondary analysis can be informative, but it does not answer every question about longer-term outcomes, other populations, or individual treatment decisions.
What we do not yet know
The indexed metadata does not disclose the exact concern raised in the Diabetes Care comment. Nor does it expose the specific reasoning offered in the reply. The response cannot be treated as a new randomized result because the public record provides no abstract or data table.[1] If the journal makes the correspondence available, those texts should be read alongside the original report rather than inferred from their headings.
For general background on the medicine, see our semaglutide resource. It cannot determine whether semaglutide is appropriate for a particular person receiving antipsychotic treatment. Readers looking for jurisdiction-specific information can also consult our Denmark regulation resources.
The practical takeaway
The new item is evidence of scientific correspondence, not evidence of a new clinical result. The accessible HISTORI secondary analysis reports improved insulin sensitivity and lower insulin resistance in its studied population. The reply letter adds a reason to read carefully, not permission to invent its contents. For decisions about medicines, a qualified healthcare professional can place the full evidence and an individual's circumstances in context.[3]
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
What does the new HISTORI record say?
PubMed identifies it as a Diabetes Care letter responding to a comment on the HISTORI secondary analysis. The record supplies bibliographic information but no abstract or letter text.
Does the reply show that the comment was wrong?
No. A response record does not disclose the correspondence's reasoning. The accessible metadata cannot establish what the comment argued or how the authors answered it.
What did the accessible HISTORI analysis report?
The full report describes a 30-week randomized, placebo-controlled trial in 154 adults receiving second-generation antipsychotics. It reported improved insulin sensitivity and lower insulin resistance with semaglutide versus placebo, while beta-cell function did not change significantly.
Does this correspondence provide treatment advice?
No. It concerns publication correspondence and a defined trial population. It does not provide personal prescribing, dosing, or medication-change guidance.
Sources
- [1]Ganeshalingam AA et al. Response to Comment on Ganeshalingam et al. Diabetes Care. 2026. PMID 42900014.Tier 1 · primary↩
- [2]Chen L, Wang J. Semaglutide Effects on Insulin Sensitivity and Beta-Cell Function. Diabetes Care. 2026. PMID 42765971.Tier 1 · primary↩
- [3]Ganeshalingam AA et al. Semaglutide Effects on Insulin Sensitivity and Beta-Cell Function: HISTORI Trial. Diabetes Care. 2026. PMID 41778920.Tier 1 · primary↩
- [4]HISTORI trial full text in Europe PMC, PMCID PMC13094869.Tier 1 · primary↩
No revisions yet. First published .